Catalyst Wire Dossier Catalyst Wire Dossier

Almonertinib

almonertinib · Jiangsu HengRui Medicine Co., Ltd.
Drug timelines are a Plus or Pro feature.

34 regulatory and trial events tracked for Almonertinib, covering 2020-07-02 to 2025-07-23. Get the full timeline:

Most recent: Clinical Trial Update: A Study of BL-B01D1 and Almonertinib in Patients With Resectable EGFR+ Stage II-IIIB NSCLC [Phase 2]

See pricing